SRC and hepatocellular carcinoma: Dasatinib, an SRC/ABL small molecular kinase inhibitor, has been approved by FDA due to the treatment of hepatocellular carcinoma [28], moreover, dasatinib inhibits cell proliferation in human esophageal squamous cell carcinoma through upregulating of the expression of MAD2 [29].